China recently approved four COVID-19 vaccines for emergency use in a span of two days. The nods were granted to Clover Biopharmaceuticals Ltd., Sinocelltech Group Ltd., Beijing Wantai Biological Pharmacy Enterprise Co. Ltd. and Westvac Biopharma Co. Ltd. There is still no mRNA vaccine approved in the country.
The Coalition for Epidemic Preparedness Innovations (CEPI) has expanded its partnership with VBI Vaccines Inc. to advance the development of multivalent coronavirus vaccines that could be deployed against COVID-19 and possible future coronaviruses with pandemic potential, referred to as coronavirus X.
The world is emerging from the COVID-19 pandemic, as both cases and deaths have remained consistently low in recent months, despite continuous mutation of the SARS-CoV-2 virus. Nevertheless, there is a shuffling of candidates in the arsenal as new variants bump once-effective therapies and the next generation of options enter the arena.
Twelve months after a single shot of Valneva SE’s chikungunya vaccine, positive antibody persistence was found, threatening a deadly disease that has long resisted treatment. The new data are derived from a study of 363 healthy adult participants that followed them from month 6 after vaccination to month 12. Nearly all, 99%, kept their neutralizing antibody titers for 12 months beyond the seroresponse threshold of 150, which hit the primary endpoint and the antibody level agreed with regulators as endpoint under the accelerated approval pathway.
The world is emerging from the COVID-19 pandemic, as both cases and deaths have remained consistently low in recent months, despite continuous mutation of the SARS-CoV-2 virus. Nevertheless, there is a shuffling of candidates in the arsenal as new variants bump once-effective therapies and the next generation of options enter the arena.
A diverse group of government and academic researchers, marking World AIDS Day 2022, have published details of an investigational vaccine they said safely induced broadly neutralizing antibody-precursors against HIV in nearly all participants in a small phase I trial.
Blue Water Vaccines Inc. has signed an exclusive, global license agreement for the development of a live attenuated, oral chlamydia vaccine candidate from The University of Texas (UT) Health San Antonio. Developed at UT Health San Antonio, the novel vaccine candidate utilizes a live attenuated chlamydia strain, Chlamydia muridarum.
Researchers from Gilead Sciences Inc. presented preclinical data for the hepatitis B virus (HBV) vaccine candidates GS-2829 and GS-6779. Conservation analysis and functional immunogenicity screening were applied to identify optimized anti-hepatitis B surface antigen (HBsAg).
MGFB, a subsidiary of Fairwinds Bio, has entered into a patent license agreement with Mayo Clinic to advance experimental cancer vaccine therapeutics based on a novel platform developed at Mayo.
CSL Ltd. subsidiary CSL Seqirus signed a licensing and development deal with Arcturus Therapeutics Inc. to in-license Arcturus’ late-stage self-amplifying mRNA vaccine platform technology. Arcturus will receive $200 million up front and is eligible to receive more than $1.3 billion in development milestones and over $3 billion in commercial milestones.
RSS
